+Vote!
Acidity Info (Free subscription) | 23/07/2008
Mylan Laboratories Inc. (NYSE: MYL) announced that the U.S. Food and Drug Administration have granted tentative esteem all for Mylan Pharmaceuticals Inc.'s Abb revia ted New Drug Application for Venlafaxine Hydrochloride Tablets 25 mg (base), 37.5 mg (base), 50 mg (base), 75 mg (base) and 100 mg (base). Ranitidine Syrup, the generic alike of GlaxoSmithKline's Zantac(R) Syrup, will be untaken in the...
+Vote!
The Pittsburgh Business Times (Free subscription) | 09/06/2008
Mylan Laboratories Inc. said Monday that it received final approval from the U.S. Food and Drug Administration to sell a generic version of King Pharmaceuticals' insomnia drug Sonata. (KG) (MYL)
+Vote!
Patent Docs (Free subscription) | 10/04/2008
By Donald Zuhn -- Last week, the Federal Circuit issued an opinion in Ortho-McNeil Pharmaceutical, Inc. v. Mylan Laboratories, Inc. In Mylan Laboratories, the Federal Circuit determined that the District Court for the District of New Jersey properly construed claim 1 of U.S. Patent No. 4,513,006, owned by Plaintiff-Appellee Ortho-McNeil...
+Vote!
Patent Docs (Free subscription) | 07/04/2008
By Donald Zuhn -- Last week, the Federal Circuit determined that the District Court for the District of New Jersey properly construed claim 1 of U.S. Patent No. 4,513,006 to encompass Plaintiff-Appellee Ortho-McNeil Pharmaceutical, Inc.'s epilepsy drug topiramate, and affirmed the District Court's decision to (1) permanently enjoin Defendants-Appellees Mylan...
+Vote!
Law Blog - WSJ.com (Free subscription) | 31/03/2008
A federal court affirmed a ruling that blocks Mylan Laboratories from selling a generic epilepsy drug until Johnson & Johnson's Topamax patent expires in September.
+Vote!
GuruFocus Updates (Free subscription) | 19/03/2008
This is the highlight of CEO buys for the past week. Related Companies: NorthStar Realty Finance Corp. (NRF), Mylan Laboratories Inc. (MYL), Helix Energy Solutions Group Inc. (HLX), General Electric Company (GE), IDT Corp. (IDT).
+Vote!
The Pittsburgh Business Times (Free subscription) | 27/02/2008
Mylan Laboratories Inc. said late Wednesday it posted a fiscal third-quarter loss due to the acquisition of Merck KGaA's generics business. (MYL) (FRX)
+Vote!
Market Watch (Free subscription) | 27/02/2008
SAN FRANCISCO (MarketWatch) -- Mylan Laboratories Inc. said late Wednesday it swung to a fiscal third-quarter loss of $1.38 billion, or $5.04 a share, from a profit of $135.4 million, or 63 cents a share, a year ago. Excluding the company's recent acquisition of Matrix Labs, the company would have reported earnings of 11 cents a share for the latest quarter. Revenue rose to $1.15 billion from $396.7...
+Vote!
Covering Your Insurance Needs (Free subscription) | 26/01/2008
BOSTON (AP)–A federal court in Washington has awarded damages of $69 million to four health insurers nearly three years after a jury found that Mylan Laboratories Inc. violated antitrust laws by overcharging for two generic versions of popular Original post by Lloyd's and Elliott Back
+Vote!
Boston Globe (Free subscription) | 26/01/2008
A federal court in Washington has awarded damages of $69 million to four health insurers nearly three years after a jury found that Mylan Laboratories Inc. violated antitrust laws by overcharging for two generic versions of popular anti-anxiety drugs.
+Vote!
Market Watch (Free subscription) | 14/11/2007
BOSTON (MarketWatch) -- Biotechnology stocks rose Wednesday, outpacing their drugmaker counterparts, as shares of Nektar Therapeutics gained for a second day.
+Vote!
Today's Tribune-Review (Free subscription) | 01/11/2007
Mylan reported a 93 percent profit increase for its most recent quarter.
+Vote!
Fool.com (Free subscription) | 30/10/2007
A Fool's prediction on the FDA's impending decision on approval.
+Vote!
Market Watch (Free subscription) | 23/10/2007
BOSTON (MarketWatch) -- Drug stocks rose in early action Tuesday, with GlaxoSmithKline Plc gaining on news that it has sold more than two million kits of its diet drug Alli since it became available without a prescription in June.
+Vote!
British Journal of Pharmacology (Free subscription) | 17/10/2007
As more blockbuster drugs come off patent, generic drugmakers face a changing landscape. Meredith Wadman looks at their strategies for survival.
